Models

Dataset Information

0

Tham2008 - PDmodel, Tumour shrinkage by gemcitabine and carboplatin


ABSTRACT: PURPOSE: This tumor response pharmacodynamic model aims to describe primary lesion shrinkage in non-small cell lung cancer over time and determine if concentration-based exposure metrics for gemcitabine or that of its metabolites,n2',2'-difluorodeoxyuridine or gemcitabine triphosphate, are better than gemcitabine dose for prediction of individual response. EXPERIMENTAL DESIGN: Gemcitabine was given thrice weekly on days 1 and 8 in combination with carboplatin, which was given only on day 1 of every cycle. Gemcitabine amount in the body and area under the concentration-time curves of plasma gemcitabine, 2',2'-difluorodeoxyuridine, and intracellular gemcitabine triphosphate in white cells were compared to determine which best describes tumor shrinkage over time. Tumor growth kinetics were described using a Gompertz-like model. RESULTS: The apparent half-life for the effect of gemcitabine was 7.67 weeks. The tumor turnover time constant was 21.8 week.cm. Baseline tumor size and gemcitabine amount in the body to attain 50% of tumor shrinkage were estimated to be 6.66 cm and 10,600 mg. There was no evidence of relapse during treatment.

SUBMITTER: Nick Holford  

PROVIDER: BIOMD0000000234 | BioModels | 2024-09-02

REPOSITORIES: BioModels

altmetric image

Publications

A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.

Tham Lai-San LS   Wang Lingzhi L   Soo Ross A RA   Lee Soo-Chin SC   Lee How-Sung HS   Yong Wei-Peng WP   Goh Boon-Cher BC   Holford Nicholas H G NH  

Clinical cancer research : an official journal of the American Association for Cancer Research 20080701 13


<h4>Purpose</h4>This tumor response pharmacodynamic model aims to describe primary lesion shrinkage in non-small cell lung cancer over time and determine if concentration-based exposure metrics for gemcitabine or that of its metabolites, 2',2'-difluorodeoxyuridine or gemcitabine triphosphate, are better than gemcitabine dose for prediction of individual response.<h4>Experimental design</h4>Gemcitabine was given thrice weekly on days 1 and 8 in combination with carboplatin, which was given only o  ...[more]

Similar Datasets

2015-04-14 | E-GEOD-66329 | biostudies-arrayexpress
2015-04-14 | GSE66329 | GEO
2009-03-24 | GSE15302 | GEO
2023-03-11 | PXD031257 | Pride
2015-11-30 | GSE69413 | GEO
2015-11-30 | GSE69412 | GEO
2010-06-21 | E-GEOD-15302 | biostudies-arrayexpress
2024-09-02 | BIOMD0000001027 | BioModels
2024-09-02 | BIOMD0000001039 | BioModels
2007-10-20 | GSE9309 | GEO